Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Weiqiong Zuo"'
Autor:
Yongxia Zhu, Tinghong Ye, Xi Yu, Qian Lei, Fangfang Yang, Yong Xia, Xuejiao Song, Li Liu, Hongxia Deng, Tiantao Gao, Cuiting Peng, Weiqiong Zuo, Ying Xiong, Lidan Zhang, Ningyu Wang, Lifeng Zhao, Yongmei Xie, Luoting Yu, Yuquan Wei
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-3 (2022)
Externí odkaz:
https://doaj.org/article/71980e2cc3a54010b98ba4437228d7db
Autor:
Qiang Xue, Zhihao Liu, Zhanzhan Feng, Ying Xu, Weiqiong Zuo, Qianqian Wang, Tiantao Gao, Jun Zeng, Xi Hu, Fanfan Jia, Yongxia Zhu, Yong Xia, Luoting Yu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 121, Iss , Pp 109598- (2020)
Lung cancer remains the leading cause of cancer mortality because of highly malignant and metastatic potential. The current status of lung cancer treatment is limited, and more treatment options are needed. Interesting, antipsychotic drugs have been
Externí odkaz:
https://doaj.org/article/bc982765bc994fa68922cb79855491c3
Autor:
Cui-Ting Peng, Zhanzhan Feng, Xi Yu, Ying Xu, Hualong He, Jun Zeng, Xuejiao Song, Luoting Yu, Xi Hu, Quan-Fang Hu, Weiqiong Zuo, Zhihao Liu, Tiantao Gao, Qian Lei
Publikováno v:
Cancer Letters. 445:11-23
The mitogen-activated protein kinase (MAPK) signaling pathway member T-LAK cell–originated protein kinase/PDZ-binding kinase (TOPK/PBK) is closely involved in tumorigenesis and progression. Its overexpression in colorectal carcinoma (CRC) exacerbat
Autor:
Weiqiong, Zuo, Yongxia, Zhu, Zhihao, Liu, Yong, Xia, Ying, Xu, Cuiting, Peng, Luoting, Yu, Ningyu, Wang
Publikováno v:
Am J Cancer Res
Targeting phosphatidylinositol 3-kinase δ (PI3Kδ) is an important therapeutic strategy for indolent non-Hodgkin lymphomas (NHLs). However, we previously observed reactivation of phosphatidylinositol 3-kinase (PI3K) pathways in aggressive NHL cell l
Autor:
Ying-Yue Yang, Qi-Wei Wang, Ning-Yu Wang, Weiqiong Zuo, Rong Hu, Qiang Feng, Ying Xu, Wan-Li Wang, Xia-Tong Hu
Publikováno v:
European Journal of Medicinal Chemistry. 227:113922
BRD4-targeted proteolysis targeting chimera (PROTAC) have exhibited promising in vitro and in vivo anticancer activity in a number of cancer models. However, the clinical development of current reported BRD4-PROTACs have stagnated, largely due to the
Autor:
Yongxia Zhu, Lijuan Chen, Hongyao Liu, Wanglai Hu, Shasha Bian, Cailin Gan, Wang Yue, Xiuli Wu, Weiqiong Zuo, Xingping Su, Tinghong Ye, Jiayu Jing, Yuqi Guo
Publikováno v:
Biochemical pharmacology. 169
The incidence of melanoma is increasing rapidly worldwide. Additionally, new and effective candidates for treating melanoma are needed because of the increase in drug resistance and the high metastatic potential of this cancer. The STAT3 signaling pa
Autor:
Jun Zeng, Weiqiong Zuo, Luoting Yu, Zhanzhan Feng, Zhihao Liu, Tiantao Gao, Xi Hu, Ning-Yu Wang, Qianqian Wang, Lifeng Zhao, Kun-Jie Xiao, Ying Xu, Xuejiao Song
Publikováno v:
Molecular cancer therapeutics. 19(6)
Castration-resistant prostate cancer (CRPC) is a lethal disease with few treatment alternatives once patients become resistant to second-generation antiandrogens. In CRPC, BET proteins are key regulators of AR- and MYC-mediated transcription, while t
Autor:
Weiqiong Zuo, Yongxia Zhu, Zhanzhan Feng, Zhihao Liu, Yong Xia, Xuejiao Song, Tiantao Gao, Cuiting Peng, Xi Hu, Qianqian Wang, Luoting Yu, Ningyu Wang
Publikováno v:
SSRN Electronic Journal.
Autor:
Xuejiao Song, Tinghong Ye, Yongxia Zhu, Weiqiong Zuo, Yong Xia, Jun Zeng, Luoting Yu, Hongxia Deng, Ningyu Wang, Lidan Zhang, Yao-Jie Shi, Tiantao Gao
Publikováno v:
Biomedicine & Pharmacotherapy. 81:482-490
Pancreatic carcinoma is a still unsolved health problem all over the world with poor prognosis and high mortality rate. YLT256, a novel synthesized chemical small inhibitor, displays potent antineoplastic activities via inducing apoptosis both in vit
Autor:
Xuejiao Song, Ningyu Wang, Cui-Ting Peng, Tiantao Gao, Lidan Zhang, Luoting Yu, Weiqiong Zuo, Li Liu, Menghua Xiong, Qiang Feng, Hongxia Deng, Suxia Shi, Yong Xia, Yongxia Zhu, Qian Lei, Xin-Yu You, Tinghong Ye
Publikováno v:
RSC Advances. 6:28512-28521
The histone methyltransferase enhancer of zeste homolog 2 (EZH2) has been reported to be overexpressed in a variety of cancers and is associated with tumor malignancy. This is mainly because EZH2 catalyzes the hypertrimethylation of histone 3 at lysi